| Literature DB >> 28257554 |
Steven T G Street1, Donovan N Chin2, Gregory J Hollingworth3, Monica Berry4, Juan C Morales5, M Carmen Galan1.
Abstract
Selective G-quadruplex ligands offer great promise for the development of anti-cancer therapies. A novel series of divalent cationic naphthalene diimide ligands that selectively bind to the hybrid form of the human telomeric G-quadruplex in K+ buffer are described herein. We demonstrate that an imidazolium-bearing mannoside-conjugate is the most selective ligand to date for this quadruplex against several other quadruplex and duplex structures. We also show that a similarly selective methylpiperazine-bearing ligand was more toxic to HeLa cancer cells than doxorubicin, whilst exhibiting three times less toxicity towards fetal lung fibroblasts WI-38.Entities:
Keywords: G-quadruplexes; antitumour agents; carbohydrates; drug design; molecular recognition
Mesh:
Substances:
Year: 2017 PMID: 28257554 PMCID: PMC5485019 DOI: 10.1002/chem.201700140
Source DB: PubMed Journal: Chemistry ISSN: 0947-6539 Impact factor: 5.236
Figure 1Structure of new NDI ligands 1–7.
Scheme 1Synthetic route to monosaccharide‐NDIs.
DNA stabilization in FRET melting assay.[a]
| Compound | F21T K+ | F21T Na+ | F‐Myc‐T | F10T |
|---|---|---|---|---|
|
| 0.4±0.1 | −0.1±0.5 | −0.3±0.4 | 0.5±0.2 |
|
| 2.9±0.3 | −1.5±0.4 | 0.9±0.7 | 0.1±0.2 |
|
| 10.1±0.3 | −1.4±0.3 | −0.3±0.7 | −0.1±0.1 |
|
| 1.3±0.4 | −0.6±0.5 | 1±0.4 | 0.4±0.2 |
|
| 3.7±0.3 | −0.5±0.4 | 1.8±0.8 | 0.1±0.1 |
|
| 9.8±0.6 | −2.3±0.3 | 0.5±0.3 | 0.3±0.2 |
|
| 2.3±0.5 | −1.5±0.2 | 3.9±0.2 | 1.1±0.1 |
[a] Displayed as ΔT max in °C. 1 μm ligand and 200 nm DNA concentration. For further information, see the Supporting Information.
Figure 2Stabilization of various DNA quadruplex and duplex sequences as a function of concentration by compound 3 and 6.
Figure 3Circular dichroism titration of 3 with telo23 K+.
Thermodynamics of binding of 3, 5 and 6 to telo23 K+ measured by ITC. K a=association constant, N=stoichiometry, ΔG=Gibbs free energy change, ΔH=enthalpy change, ΔS=entropy change and T=temperature. Error (in brackets) represents a confidence interval of 68.3 %. For more information, see the Supporting Information.
| Compound |
|
|
|
|---|---|---|---|
|
| 1.30 (1.02,1.64) | 2.16 (1.85,2.52) | 1.03 (0.865,1.23) |
|
| 2.7–2.6 | 2.0–1.9 | 1.9–2.0 |
| Δ | −8.34 | −8.64 | −8.20 |
| Δ | −10.0 (−8.80, −11.9) | −13.9 (−13.4, −14.4) | −14.5 (−13.7, −15.4) |
| Δ | −5.55 | −17.6 | −21.0 |
|
| 298 | 298 | 298 |
Figure 4Model of 3 bound to the parallel K+ human telomeric G‐quadruplex (based on PDB ID: 4DA3). See the Supporting Information for further details.
Cytotoxicity of 1–7 and doxorubicin (Dox) after 72 h incubation.[a]
|
|
|
|
| |
|---|---|---|---|---|
|
| 1.19 (1.05, 1.33) | 0.53 (0.42, 0.62) | 0.43 (0.37, 0.50) | 0.80 (0.66, 0.97) |
|
| >100 | >100 | >100 | >100 |
|
| >100 | >100 | >100 | >100 |
|
| >100 | >100 | >100 | >100 |
|
| 21.46 (16.39, 28.10) | 6.23 (4.35, 8.92) | 52.76 (38.41, 72.48) | n/m |
|
| 40.22 (28.83, 56.11) | 3.63 (2.59, 5.08) | 11.77 (9.67, 14.33) | n/m |
|
| 2.28 (2.10, 2.47) | 0.41 (0.35, 0.47) | 3.09 (2.83, 3.38) | 0.81 (0.66, 1.01) |
|
| 0.72 (0.67, 0.76) | 0.38 (0.32, 0.46) | 0.53 (0.48, 0.58) | 8.10 (6.73, 9.74) |
[a] Absolute IC50 values measured in μm using calcein fluorescence to assess live cells, with 95 % confidence interval in brackets. For metabolic effects (Alamar Blue Assay) see the Supporting Information. n/m=Non monotonic dose response observed.
Figure 5HeLa Cell uptake of 3 and 6 monitored by fluorescence confocal microscopy. Fluorescence images and the merged bright‐field/fluorescence images of: A and E) untreated control; B and F) after 30 min exposure to 100 μm of 6; C and G) after 30 min exposure to 100 μm of 3; D and H) after 16 h exposure to 100 μm of 3. For more information, see the Supporting Information.